Quick Answer
Axsome Therapeutics, Inc. reported Total Assets of $689.81 million for the year ending 2025.
- Axsome Therapeutics, Inc. showed an increase of +21.3% in Total Assets from 2024 to 2025.
- This data is from Axsome Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $45.15 million | Q2 2016: $40.01 million | Q3 2016: $34.92 million | Q1 2017: $46.41 million | Q2 2017: $39.04 million | Q3 2017: $32.62 million | Q1 2018: $27.94 million | Q2 2018: $21.73 million | Q3 2018: $16.13 million | Q1 2019: $43.90 million | Q2 2019: $54.78 million | Q3 2019: $44.44 million | Q1 2020: $197.80 million | Q2 2020: $190.99 million | Q3 2020: $203.63 million | Q1 2021: $166.90 million | Q2 2021: $143.26 million | Q3 2021: $116.60 million | Q1 2022: $88.56 million | Q2 2022: $180.56 million | Q3 2022: $338.96 million | Q1 2023: $389.18 million | Q2 2023: $611.64 million | Q3 2023: $600.86 million | Q1 2024: $545.73 million | Q2 2024: $548.23 million | Q3 2024: $561.46 million | Q1 2025: $596.67 million | Q2 2025: $639.79 million | Q3 2025: $669.25 million.
- Over the full 11 years of available data (2015 to 2025), Axsome Therapeutics, Inc.'s Total Assets has grown by 1,305.6%.
- Historical annual values: Fiscal year 2025: $689.81 million | Fiscal year 2024: $568.50 million | Fiscal year 2023: $588.24 million | Fiscal year 2022: $331.48 million | Fiscal year 2021: $87.79 million | Fiscal year 2020: $186.13 million | Fiscal year 2019: $220.55 million | Fiscal year 2018: $15.38 million | Fiscal year 2017: $35.56 million | Fiscal year 2016: $38.21 million | Fiscal year 2015: $49.08 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: